This page is a work in progress - it does not represent CIMI policy or consensus
- 1 Caveat
- 2 The CIMI principles
- 3 Implications of the CIMI principles
- 4 Types of Clinical Information Modelling Initiative Specification
The CIMI principles
- CIMI specifications will be freely available to all. The initial use cases will focus on the requirements of organisations involved in providing, funding, monitoring or governing healthcare and to providers of healthcare IT and healthcare IT standards as well as to national eHealth programs, professional organisations, health providers and clinical system developers.
- CIMI is committed to making these specifications available in a number of formats, beginning with the Archetype Definition Language (ADL) from the openEHR Foundation (ISO 13606.2) and the Unified Modelling Language (UML) from the Object Management Group (OMG) with the intent that the users of these specifications can convert them into their local formats.
- CIMI is committed to transparency in its work product and process.
Implications of the CIMI principles
Freely available to all
CIMI specifications will be available
- without hindrance to access or use
- without financial or other payment
This imposes the following requirements for CIMI specifications:
- any CIMI specification should be shared with intellectual property rights
- the details of the licence should be included in the CIMI specifications
- These right will enable contributors and consumers to
- copy, publish, distribute and transmit the intellectual property;
- adapt the intelelctual property;
- exploit the intellectual property commercially
- The intellectual property rights should be a worldwide, perpetual, non-exclusive licence
- It is reasonable, but not necessary, to request the source of the intellectual property is attributed, including prescribing an attribution statement
- The licence should indicate the jurisdiction it is governed in, which will normally be the principle jurisdiction of the the intellectual property owner
- The licence should include the extent of any warranty
- The intellectual property rights should be royalty free
These requirements can be seen as the quality criteria for the licence for CIMI specifications.
Underpinning / foundation intellectual properties
For this principle to be discharged, any underpinning or foundation intellectual property (such as reference models, reference terminologies or infrastructure) must be licenced in a manner which enables CIMI specifications to be shared with a licence which meets these quality criteria. It does not necessarily require the licence for the underpinning or foundation intellectual property to conform to these quality criteria.
Available in a number of formats
Each Clinical Information Model should be capable of transformation into multiple structural and serialisation formats. Template:DecisionRequired For a fully specified Clinical Information Model it should fully express the semantics of the model so that other iso-semantic models can be identified / created. The quality criteria for a fully semantic model are not yet defined.
CIMI specifications will be available to view and review throughout their development and assurance. This will include specifications which have not been adopted and models which are not declared fit for any particular purpose.
Types of Clinical Information Modelling Initiative Specification
The following examples of types of Clinical Information Modelling Initiative Specification may exist:
|Type of specification||Examples||CIMI governance requirements||Comments|
|Clinical Information Model||
||CIMI will need to specify the quality criteria for a model.
Conformance to these quality criteria may be asserted by the model contributor / developer or by CIMI
These models will be safety critical.
These models are the principle reason for CIMI.
For any particular use case there may be multiple models contributed. These may be Isosemantic Models, incomplete or incompatible with each other.
|CIMI Reference Model||CIMI will require governance in the initial stages of development but in due course governance should pass to a recognised Standards Development Organisation. Once passed to an SDO CIMI governance should be through that SDO.||CIMI is expected to have one reference model|
|Reference Terminology||None||Governance of the reference terminologies will be controlled by the owner of that Reference Terminology|
|CIMI terminology extension||A CIMI SNOMED CT extension||A governance conformant with the quality criteria set by the owner of that reference terminology|
|Terminology Bindings||A Terminology Binding using a Reference Set can only be assured against specific releases of a Reference Terminology. A terminology binding should therefore include advice on the issues involved in transferring the terminology binding to a different realm or extension.|
|Model transformations||Governed by the sub-set of members with an interest in that transformation||The model transformations must specify whether the transformation is lossy or enables a round trip (i.e. formalism 1 => formalism 2 => formalism 1) without loss of meaning or functionality|
A suggested lifecycle of a CIMI clinical information model
A CIMI Clinical Information Model is expected to follow a development cycle however the initial phases of development may well occur outside CIMI. The expected steps are described in the table below.
|Stage||Governance within CIMI||Key products see note below||Responsible||Accountable||Contributors||Other involved|
||Any CIMI member||The responsible CIMI member||
Selected by by the responsible member
The contributors may refine the business challenge / problem statement and requirements
|Selected by the responsible member|
Set of responses / contributions in response to the business challenge and clinical requirements. Each contribution will include
Each contribution may include
|CIMI Members||The initiating CIMI member||Any global contributor||Open for global involvement|
|Consolidate and build||Optional||
||To be allocated by developer||To be allocated by developer||Any CIMI contributor||Open for global involvement|
|Testing and assurance||
Optional for member use
Required for CIMI approval
Selected by initiating member for member use
Allocated by CIMI membership for CIMI approval
|Any CIMI contributor||Open for global involvement|
Optional for member use
Required for CIMI approval
|Repository manager||Member, or CIMI if CIMI approved Clinical Information Model||None||Open for global consumption if CIMI approved Clinical Information Model|
Note: The key products are additive, that is for completion of a development stage the quality key products of all previous stages must be assured.